Please use this identifier to cite or link to this item:
Title: Convalescent plasma and all-cause mortality of COVID-19 patients: systematic review and meta-analysis
Authors: Nora Mihalek
Dragana Radovanović 
Otto Barak 
Petar Čolović 
Markus Huber
Gabor Erdoes
Keywords: Bias;COVID-19;Immunization, Passive;COVID-19 Serotherapy;SARS-CoV-2
Issue Date: 9-Aug-2023
Journal: Scientific Reports
Abstract: Insight into the clinical potential of convalescent plasma in patients with coronavirus disease (COVID-19) is important given the severe clinical courses in unvaccinated and seronegative individuals. The aim of the study was to investigate whether there is a survival benefit of convalescent plasma therapy in COVID-19 patients. The authors independently assessed randomized controlled trials (RCTs) identified by the search strategy for inclusion, extracted data, and assessed risk of bias. The binary primary outcome was all-cause mortality. Risk ratio (RR) of the convalescent plasma treatment (vs. best standard care) and its associated standard error (effect size) were calculated. A random-effects model was employed to statistically pool the effect sizes of the selected studies. We included 19 RCTs with 17,021 patients. The random-effects model resulted in an estimated pooled RR of 0.94 (95% CI 0.81–1.08, p = 0.33), showing no statistical evidence of the benefit of convalescent plasma therapy on all-cause mortality. Convalescent plasma therapy was not found to be effective in reducing all-cause mortality in COVID-19 patients. Further studies are needed to determine in which patients convalescent plasma therapy may lead to a reduction in mortality.
ISSN: 2045-2322
Rights: Attribution 3.0 United States
Appears in Collections:FF Publikacije/Publications

Files in This Item:
File Description SizeFormat
s41598-023-40009-8.pdf2.22 MBAdobe PDFView/Open
Show full item record

Page view(s)

Last Week
Last month
checked on May 10, 2024


checked on May 10, 2024

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons